NeOnc Technologies Holdings Inc
NTHI9.770USD
+0.530+5.74%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
190.26MValor de mercado
PerdaP/L TTM
Mais detalhes de NeOnc Technologies Holdings Inc Empresa
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Informações de NeOnc Technologies Holdings Inc
Código da empresaNTHI
Nome da EmpresaNeOnc Technologies Holdings Inc
Data de listagemMar 26, 2025
CEOHeshmatpour (Amir F)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 26
Endereço23975 Park Sorrento
CidadeCALABASAS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91302
Telefone13106637831
Sitehttps://neonc.com/
Código da empresaNTHI
Data de listagemMar 26, 2025
CEOHeshmatpour (Amir F)
Executivos da empresa NeOnc Technologies Holdings Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Hon. Jim Delshad
Hon. Jim Delshad
Independent Director
Independent Director
--
--
Ms. Laurie Berman
Ms. Laurie Berman
Investor Relations
Investor Relations
--
--
Mr. Josh Neman
Mr. Josh Neman
Chief Clinical Officer
Chief Clinical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qua, 17 de dez
Atualizado em: qua, 17 de dez
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Chen (Thomas C.)
22.52%
AFH Holding & Advisory, L.L.C.
19.07%
Heshmatpour (Amir Farrokh)
18.18%
Chiang (Ming-Fu Alan)
7.22%
HighPoint Advisor Group, LLC
5.88%
Outro
27.12%
Investidores
Investidores
Proporção
Chen (Thomas C.)
22.52%
AFH Holding & Advisory, L.L.C.
19.07%
Heshmatpour (Amir Farrokh)
18.18%
Chiang (Ming-Fu Alan)
7.22%
HighPoint Advisor Group, LLC
5.88%
Outro
27.12%
Tipos de investidores
Investidores
Proporção
Individual Investor
50.16%
Corporation
24.33%
Investment Advisor
8.14%
Research Firm
1.26%
Investment Advisor/Hedge Fund
0.93%
Outro
15.18%
Participação acionária institucional
Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
23
1.79M
3.13%
--
2025Q4
23
2.03M
10.43%
+550.00K
2025Q3
17
1.61M
8.43%
+1.29M
2025Q2
18
10.40M
54.67%
-137.09K
2025Q1
15
8.72M
46.52%
+8.72M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Chen (Thomas C.)
4.39M
22.52%
+1.54M
+54.01%
Dec 12, 2025
AFH Holding & Advisory, L.L.C.
3.71M
19.07%
--
--
Dec 12, 2025
Heshmatpour (Amir Farrokh)
3.54M
18.18%
+1.19M
+50.60%
Dec 12, 2025
Chiang (Ming-Fu Alan)
1.41M
7.22%
+967.76K
+220.64%
Dec 12, 2025
HighPoint Advisor Group, LLC
950.23K
4.88%
+769.16K
+424.79%
Sep 30, 2025
HCWG LLC
1.02M
5.26%
--
--
Dec 12, 2025
BofA Global Research (US)
226.49K
1.16%
+2.21K
+0.98%
Sep 30, 2025
The Vanguard Group, Inc.
140.91K
0.72%
+140.91K
--
Sep 30, 2025
Garnett (Keithly)
161.35K
0.83%
+160.45K
+17828.00%
Dec 12, 2025
BlackRock Institutional Trust Company, N.A.
148.51K
0.76%
+143.40K
+2807.44%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
